Catalytic Combinations for Prostate Cancer and Beyond

Illuminating the science behind an ongoing clinical trial, Professor Michael Yaffe and his clinical and biotech collaborators tell the story of how a synergistic drug combination discovered at the Koch Institute revived an all but forgotten drug class and shows great promise for combatting resistant tumors. Beth Israel Deaconess Medical Center’s David Einstein shares clinical perspectives from the trial, and Trovagene’s Mark Erlander talks about the Plk-1 inhibitor that proved crucial for the introduction of this combination into prostate cancer. Achieving more together than they ever could on their own, this dynamic team embodies the powerful synergy they are bringing to patients.

Featured Presenters

Michael B. Yaffe, MD, PhD

Director, MIT Center for Precision Cancer Medicine
David H. Koch Professor of Science
Professor of Biology and Biological Engineering

Jesse Patterson, PhD

Postdoctoral Fellow, Yaffe Lab, Koch Institute

David Einstein, MD

Medical Oncologist, Beth Israel Deaconess Medical Center
Instructor, Medicine, Harvard Medical School

Mark Erlander, PhD

Chief Scientific Officer, Trovagene Oncology

Related News